
Q8, Q9, and Q10 Questions and Answers (R5) Guidance for Industry

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)**

**May 2026
ICH-Quality**

Q8, Q9, and Q10 Questions and Answers (R5)

Additional copies are available from:

*Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
Phone: 855-543-3784 or 301-796-3400
Email: druginfo@fda.hhs.gov*

<https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs>

and/or

*Office of Communication, Outreach, and Development
Center for Biologics Evaluation and Research
Food and Drug Administration*

Phone: 800-835-4709 or 240-402-8010; Email: industry.biologics@fda.hhs.gov

<https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances>

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)**

**May 2026
ICH-Quality**

Contains Nonbinding Recommendations

FOREWORD

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has the mission of achieving greater regulatory harmonization worldwide to ensure that safe, effective, and high-quality medicines are developed, registered, and maintained in the most resource-efficient manner. By harmonizing the regulatory expectations in regions around the world, ICH guidelines have substantially reduced duplicative clinical studies, prevented unnecessary animal studies, standardized safety reporting and marketing application submissions, and contributed to many other improvements in the quality of global drug development and manufacturing and the products available to patients.

ICH is a consensus-driven process that involves technical experts from regulatory authorities and industry parties in detailed technical and science-based harmonization work that results in the development of ICH guidelines. The commitment to consistent adoption of these consensus-based guidelines by regulators around the globe is critical to realizing the benefits of safe, effective, and high-quality medicines for patients as well as for industry. As a Founding Regulatory Member of ICH, the Food and Drug Administration (FDA) plays a major role in the development of each of the ICH guidelines, which FDA then adopts and issues as guidance to industry.

TABLE OF CONTENTS

(PREFACE)	1
I. INTRODUCTION (1)	2
A. For General Clarification (1.1)	2
II. QUALITY BY DESIGN TOPICS (2)	3
A. Design Space (2.1)	3
B. Real Time Release Testing (RTRT) (2.2)	5
C. Control Strategy (2.3)	7
III. PHARMACEUTICAL QUALITY SYSTEM (3)	9
IV. ICH QUALITY GUIDELINES' IMPACT ON GMP INSPECTION PRACTICES (4)	11
V. KNOWLEDGE MANAGEMENT (5)	12
VI. SOFTWARE SOLUTIONS (6)	14
REFERENCES	15

Contains Nonbinding Recommendations

Q8, Q9, and Q10 Questions and Answers (R5) Guidance for Industry¹

This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA office responsible for this guidance as listed on the title page.

(PREFACE)

This International Council for Harmonisation (ICH) guidance for industry *Q8, Q9, and Q10 Questions and Answers (R5)* (ICH Q8, Q9, and Q10 (R5)) provides answers to a number of questions which are relevant to the implementation of the ICH guidances for industry *Q8(R2) Pharmaceutical Development* (ICH Q8(R2)) (November 2009), *Q9(R1) Quality Risk Management* (ICH Q9(R1)) (May 2023), and *Q10 Pharmaceutical Quality System* (ICH Q10) (April 2009).² This guidance revises and updates the November 2011 ICH guidance titled *Q8, Q9, and Q10 Questions and Answers (R4)*.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended but not required.

¹ This guidance was developed within the Expert Working Group *Quality* of the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and has been subject to consultation by the regulatory parties, in accordance with the ICH process. This document has been endorsed by the ICH Assembly at *Step 4* of the ICH process, October 2024. At *Step 4* of the process, the final draft is recommended for adoption to the regulatory bodies of the ICH regions. Submit comments to Docket No. FDA-2017-D-6821 (available at <https://www.regulations.gov/docket?D=FDA-2017-D-6821>). See the instructions in that docket for submitting comments on this and other Level 2 guidances.

² We update guidances periodically. To make sure you have the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>.

I. INTRODUCTION (1)³

A. For General Clarification (1.1)

Table 1. Q&A for Section I (1) of ICH Q8, Q9, and Q10 (R5)

Date of Approval		Questions	Answers
1	June 2009	Is the minimal approach accepted by regulators?	Yes. The minimal approach as defined in ICH Q8(R2) (sometime also called ‘baseline’ or ‘traditional’ approach) is the expectation which is to be achieved for a fully acceptable submission. However, the ‘enhanced’ approach as described in ICH Q8(R2) is encouraged (Ref. ICH Q8(R2), Appendix 1).
2	Oct. 2009	What is an appropriate approach for process validation using ICH Q8, Q9 and Q10?	The objectives of process validation are unchanged when using ICH Q8, Q9 and Q10. The main objective of process validation remains that a process design yields a product meeting its pre-defined quality criteria. ICH Q8, Q9 and Q10 provide a structured way to define product critical quality attributes, design space, the manufacturing process, and the control strategy. This information can be used to identify the type and focus of studies to be performed prior to and on initial commercial production batch. As an alternative to the traditional process validation, continuous process verification (see definition in ICH Q8(R2) glossary) can be utilized in process validation protocols for the initial commercial production and for manufacturing process changes for the continual improvement throughout the remainder of the product lifecycle.
3	Oct. 2024	How can information from quality risk management and continuous process verification provide for a robust continual improvement approach under ICH Q8, Q9 and Q10?	Like the product itself, process validation also has a lifecycle (process design, process qualification, and ongoing process verification). A risk assessment conducted prior to initial commercial validation batches can highlight the areas where particular focus and data are needed to demonstrate a high level of assurance of commercial process robustness. Continual monitoring (e.g., via Continuous Process Verification) can further demonstrate the actual level of assurance of process consistency and provide the basis for continual improvement of the product. Quality Risk Management methodologies of ICH Q9(R1) can be applied throughout the product lifecycle to maintain a state of process control.

³ The numbers in parentheses reflect the organizational breakdown of the document endorsed by the ICH Assembly at Step 4 of the ICH process, October 2024.

II. QUALITY BY DESIGN TOPICS (2)

Table 2. Q&A for Section II (2) of ICH Q8, Q9, and Q10 (R5)

Date of Approval		Questions	Answers
1	Oct. 2024	Is it always necessary to have a Design Space (DS) or Real Time Release Testing (RTRT) to implement QbD?	Under Quality by Design, establishing a design space or using RTRT is not necessarily expected (see ICH Q8(R2)).

A. Design Space (2.1)

1	Apr. 2009	Is it necessary to study multivariate interactions of all parameters to develop a design space?	No, the applicant will need to justify the choice of material attributes and parameters for multivariate experimentation based on risk assessment and desired operational flexibility.
2	Oct. 2024	Can a design space be applicable to scale-up?	Yes, when appropriately justified (additional details see ICH Q8(R2), Section II.D.4 (2.4.4), “Relationship of Design Space to Scale and Equipment”).
3	Oct. 2024	Can a design space be applicable to a site change?	Yes, it is possible to justify a site change using a site independent design space based on a demonstrated understanding of the robustness of the process and an in-depth consideration of site-specific factors, e.g., materials, equipment, personnel, utilities, manufacturing environment, and equipment. There are region-specific regulatory requirements associated with site changes that need to be followed.
4	Apr. 2009	Can a design space be developed for single and/or multiple-unit operations?	Yes, it is possible to develop a design space for single unit operations or across a series of unit operations (see ICH Q8(R2), Section II.D.3 (2.4.3), “Unit Operation Design Space(s)”).
5	Oct. 2024	Is it possible to develop a design space for existing products?	Yes, it is possible. Manufacturing data and process knowledge can be used to support a design space for existing products. Relevant information should be utilized from e.g., commercial scale manufacturing, raw materials, process improvement, CAPAs, development data, and relevant knowledge from risk review. For manufacturing operations run under narrow operational ranges in fixed equipment, an expanded region of operation and an understanding of multi-parameter

Contains Nonbinding Recommendations

			interactions may not be achievable from existing manufacturing data alone and additional studies may be needed to develop a design space. Sufficient knowledge should be demonstrated, and the design space should be supported experimentally to investigate interactions and establish parameter/attribute ranges.
6	Apr. 2009	Is there a regulatory expectation to develop a design space for an existing product?	No, development of a design space for existing products is not necessary unless the applicant has a specific need and desires to use a design space to achieve a higher degree of product and process understanding. This may increase manufacturing flexibility and/or robustness.
7	Jun. 2009	Can a design space be applicable to formulation?	Yes, it may be possible to develop formulation (not component but rather composition) design space consisting of the ranges of excipient amount and its physicochemical properties (e.g., particle size distribution, substitution degree of polymer) based on an enhanced knowledge over a wider range of material attributes. The applicant should justify the rationale for establishing the design space with respect to quality attributes such as bioequivalence, stability, manufacturing robustness, etc. Formulation adjustment within the design space depending on material attributes does not need a submission in a regulatory post approval change.
8	Jun. 2009	Does a set of proven acceptable ranges alone constitute a design space?	No, a combination of proven acceptable ranges (PARs) developed from univariate experimentation does not constitute a design space (see ICH Q8(R2), Section II.D.5 (2.4.5), “Design Space Versus Proven Acceptable Ranges”). Proven acceptable ranges from only univariate experimentation may lack an understanding of interactions between the process parameters and/or material attributes. However, proven acceptable ranges continue to be acceptable from the regulatory perspective but are not considered a design space (see ICH Q8(R2), Section II.D.5 (2.4.5), “Design Space Versus Proven Acceptable Ranges”). The applicant may elect to use proven acceptable ranges or design space for different aspects of the manufacturing process.
9	Oct. 2024	Should the outer limits of the Design Space be evaluated during process validation studies at the commercial scale?	No, there is no need to run the process qualification batches at the outer limits of the design space during process validation studies at commercial scale. The design space must be sufficiently explored earlier during development studies (for scale up, see also page 3, Section II.A (2.1), “Design Space Question 2”; for life cycle approach see page 2, Section A (1.1), “For General Clarification” to Question 3).

Contains Nonbinding Recommendations

B. Real Time Release Testing (RTRT) (2.2)

Date of Approval		Questions	Answers
1	Oct. 2024	How is batch release affected by employing RTRT?	Batch release is the final decision to release the product to the market regardless of whether RTRT or end product testing is employed. End product testing involves performance of specific analytical procedures on a defined sample size of the final product after completion of all processing for a given batch of that product. Results of RTRT are handled in the same manner as end product testing results in the batch release decision. Batch release involves an independent review of batch conformance to predefined criteria through the review of testing results and manufacturing records, together with an effective quality system that ensures GM P compliance, regardless of which approach is used.
2	Apr. 2009	Does RTRT mean elimination of end product testing?	RTRT does not necessarily eliminate all end product testing. For example, an applicant may propose RTRT for some attributes only or not all. If all CQAs (relevant for RTRT) are assured by in-process monitoring of parameters and/or testing of materials, then end product testing might not be needed for batch release. Some product testing will be expected for certain regulatory processes such as stability studies or regional requirements.
3	Apr. 2009	Is a product specification still necessary in the case of RTRT?	Yes, product specifications (see the ICH guidelines <i>Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances</i> (finalized October 6, 1999) and <i>Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products</i>) (finalized March 10, 1999) still need to be established and met, when tested.
4	Oct. 2024	When using RTRT, is there a need for stability test methods?	Even where RTRT is applied, a stability monitoring protocol that uses stability-indicating methods is required for all products regardless of the means of release testing (see the ICH guidances for industry <i>Q1A(R2) Stability Testing of New Drug Substances and Products</i> (November 2003) and <i>Q5C Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products</i> (July 1996)).

Contains Nonbinding Recommendations

Date of Approval		Questions	Answers
5	Oct. 2024	What is the relationship between Control Strategy and RTRT?	RTRT, if utilized, is an element of the Control Strategy and may enable appropriate in-process testing (in-line, on-line, at-line) of quality attributes rather than testing on the end product. This use of RTRT recognizes that under specific circumstances an appropriate combination of process controls (critical process parameters) together with pre-defined material attributes may provide greater assurance of product quality than end product testing and as such be an integral part of the control strategy.
6	Oct. 2024	Do traditional sampling approaches apply to RTRT?	No, traditionally sampling plans for in-process and end-product testing involve a discrete sample size that represents the minimal sampling expectations. Generally, the use of RTRT will include more extensive on-line/in-line measurements. A scientifically sound sampling approach should be developed, justified, and implemented.
7	Oct. 2024	If RTRT results fail or trending toward failure, can end-product testing be used to release the batch?	No, in principle the RTRT results should be routinely used for the batch release decisions and not be substituted by end-product testing. Any failure should be investigated, and trending should be followed up appropriately. However, batch release decisions will need to be made based on the results of the investigations. The batch release decision needs to comply with the content of the marketing authorization and GMP compliance.
8	Oct. 2024	What is the relationship between in-process testing and RTRT?	In-process testing includes any testing that occurs during the manufacturing process of drug substance and/or finished product. RTRT includes those in-process tests that directly impact the decision for batch release through evaluation of Critical Quality Attributes.
9	Jun. 2009	What is the difference between ‘real time release’ and ‘RTRT’?	The definition of RTRT in ICH Q8(R2) is “the ability to evaluate and ensure the acceptable quality of in- process and/or final product based on process data, which typically includes a valid combination of measured material attributes and process controls.” The term ‘Real time release’ in the ICH Q8(R2), Step 2 document was revised to RTRT in the final ICH Q8(R2) Part II document to fit the definition more accurately and thus avoid confusion with batch release.
10	Oct. 2024	Can a surrogate measurement be used for RTRT?	Yes, RTRT can be based on measurement of surrogate (e.g., process parameter, material attribute) that has been demonstrated to correlate with an in-process or end-product specification (see ICH Q8(R2); Section II.E (2.5)).

Contains Nonbinding Recommendations

Date of Approval		Questions	Answers
11	Oct. 2024	What is the relationship between RTRT and Parametric Release?	Parametric release is one type of RTRT. Parametric release is based on process data (e.g., temperature, pressure, time for terminal sterilization, physicochemical indicator) rather than the testing of material and/or a sample for a specific attribute.

C. Control Strategy (2.3)

Refer to the definition of control strategy provided in the ICH Q10 glossary definition:

A planned set of controls, derived from current product and process understanding that assures process performance and product quality. The controls can include parameters and attributes related to drug substance and drug product materials and components, facility and equipment operating conditions, in-process controls, finished product specifications, and the associated methods and frequency of monitoring and control.

Date of Approval		Questions	Answers
1	Apr. 2009	What is the difference in a control strategy for products developed using the minimal approach versus ‘quality-by-design’ approach?	Control strategies are expected irrespective of the development approach. Control strategy includes different types of control proposed by the applicant to assure product quality (see ICH Q10, Section III.B.1 (3.2.1), “Process Performance and Product Quality Monitoring System”), such as in-process testing and end-product testing. For products developed following the minimal approach, the control strategy is usually derived empirically and typically relies more on discrete sampling and end product testing. Under QbD, the control strategy is derived using a systematic science and risk-based approach. Testing, monitoring, or controlling is often shifted earlier into the process and conducted in-line, on-line or at-line testing.
2	Apr. 2009	Are GMP requirements different for batch release under QbD?	No, the same GMP requirements apply for batch release under minimal and QbD approaches.
3	Apr. 2009	What is the relationship between a Design Space and a Control Strategy?	A control strategy is required for all products. If a Design Space is developed and approved, the Control Strategy (see ICH Q8(R2), Section II.D (2.4), “Design Space”) provides the mechanism to ensure that the manufacturing process is maintained within the boundaries described by the Design Space.

Contains Nonbinding Recommendations

Date of Approval		Questions	Answers
4	Jun. 2009	What approaches can be taken in the event of on-line/in-line/at-line testing or monitoring equipment breakdown?	The control strategy provided in the application should include a proposal for use of alternative testing or monitoring approaches in cases of equipment failure. The alternative approach could involve use of end product testing or other options, while maintaining an acceptable level of quality. Testing or monitoring equipment breakdown needs to be managed in the context of a deviation under the Quality System and can be covered by GMP inspection.
5	Oct. 2009	Are product specifications different for minimal versus QbD approaches?	In principle, no, the same product specifications are needed for minimal and QbD approaches. For a QbD approach, the control strategy may allow achieving the end product specifications via RTRT approaches (see ICH Q8(R2), Appendix 1). Product must meet specifications when tested.

III. PHARMACEUTICAL QUALITY SYSTEM (3)

Table 3. Q&A for Section III (3) of ICH Q8, Q9, and Q10 (R5)

Date of Approval		Questions	Answers
1	Oct. 2024	What are the benefits of implementing a Pharmaceutical Quality System (in accordance with ICH Q10)?	<p>The benefits are:</p> <ul style="list-style-type: none"> • A robust manufacturing process, through facilitation of continual improvement through science and risk-based post approval change processes; • Consistency in the global pharmaceutical environment across regions; • Transparency of systems, processes, organizational and management responsibility within, and across, companies (e.g., contract organizations); • Clearer understanding of the application of the Pharmaceutical Quality System throughout product lifecycle; • Further reduced risk of product failure and incidence of complaints and recalls, thereby providing greater assurance of pharmaceutical product consistency and availability (supply) to the patient; • Better process performance, supported by effective risk reviews; • Opportunities to increase understanding between industry and regulators and more optimal use of industry and regulatory resources. Enhanced manufacturers and regulators' confidence in product quality; • Greater assurance of compliance with GMP, which builds confidence in the regulators, and which may result in shorter inspections. • Knowledge-driven and objective risk assessments which help achieve science-and risk-based control strategies, and which lead to effective risk-based decisions as well as reduced product availability risks relating to quality/manufacturing issues.

Contains Nonbinding Recommendations

Date of Approval		Questions	Answers
2	Apr. 2009	How does a company demonstrate implementation of PQS in accordance with ICH Q10?	When implemented, a company will demonstrate the use of an effective PQS through its documentation (e.g., policies, standards), its processes, its training/qualification, its management, its continual improvement efforts, and its performance against pre-defined Key Performance Indicators (see ICH Q10 glossary on ‘Performance indicator’). A mechanism should be established to demonstrate at a site how the PQS operates across the product lifecycle, in an easily understandable way for management, staff and regulatory inspectors, e.g., a quality manual, documentation, flowcharts, procedures. Companies can implement a program in which the PQS is routinely audited in-house (i.e., internal audit program) to ensure that the system is functioning at a high level.
3	Oct. 2024	Is it necessary to describe the PQS in a regulatory submission?	No, however relevant elements of the PQS, such as quality monitoring system, change management, and deviation management may be referenced as part of the control strategy as supporting information.
4	Oct. 2024	Is there certification that the PQS is in accordance with ICH Q10?	No. There is no specific ICH Q10 certification program.
5	Apr. 2009	How should the implementation of the design space be evaluated during inspection of the manufacturing site?	Inspection should verify/assess that manufacturing operations are appropriately carried out within the Design Space. The inspector in collaboration with the assessor, where appropriate, should also verify successful manufacturing operations under the Design Space and that movement within the Design Space is managed within the company’s change system (see ICH Q10, Section III.B (3.2), Table III).
6	Apr. 2009	What should be done if manufacturing operations run inadvertently outside of the Design Space?	This should be handled as a deviation under GMP. For example, unplanned ‘one-off’ excursions occurring as a result of unexpected events, such as operator error or equipment failure, would be investigated, documented, and dealt with as a deviation in the usual way. The results of the investigation may contribute to the process of knowledge, preventive actions, and continual improvement of the product.

Contains Nonbinding Recommendations

Date of Approval		Questions	Answers
7	Oct. 2024	What information and documentation of the development studies should be available at a manufacturing site?	<p>Pharmaceutical development information (e.g., supporting information on design space, chemometric model, outputs of quality risk management activities) is available at the development site. Pharmaceutical development information which is useful to ensure the understanding of the basis for the manufacturing process and control strategy, including the rationale for selection of critical process parameters and critical quality attributes should be available at the manufacturing site.</p> <p>Scientific collaboration and knowledge sharing between pharmaceutical development and manufacturing are essential to ensure the successful transfer to production.</p>
8	Jun. 2009	Can process parameters be adjusted throughout the product lifecycle?	<p>Process parameters are studied and selected during pharmaceutical development and monitored during commercial manufacturing. Knowledge gained could be utilized for adjustment of the parameters as part of continual improvement of the process throughout the lifecycle of the drug product (see ICH Q10, Section III (3), “Management Responsibility”).</p>

IV. ICH QUALITY GUIDELINES’ IMPACT ON GMP INSPECTION PRACTICES (4)

Table 4. Q&A for Section IV (4) of ICH Q8, Q9, and Q10 (R5)

Date of Approval		Questions	Answers
1	Oct. 2024	How do product-related inspections differ in an ICH Q8, Q9, and Q10 environment?	<p>In the case of product-related inspection (in particular pre-authorization) depending on the complexity of the product and/or process, there may be a need for greater collaboration between inspectors and assessors, for example, for the assessment of development data. The inspection would normally occur at the proposed commercial manufacturing site and there may be greater focus on enhanced process understanding and understanding relationships, e.g., Critical Quality Attribute (CQAs), Critical Process Parameters (CPPs). It may also extend into the application and implementation of quality risk management principles, as supported by the Pharmaceutical Quality System (PQS).</p>

Contains Nonbinding Recommendations

Date of Approval		Questions	Answers
2	Oct. 2024	How do system-related inspections differ in an ICH Q8, Q9 and Q10 environment?	Such inspections have greater focus (but not only) on how the PQS facilitates the use of e.g., Quality Risk Management methods, implementation of design space and change management (see ICH Q10).
3	Oct. 2024	How is control strategy approved in the application and evaluated during inspection?	Elements of the control strategy submitted in the application are reviewed and approved by the regulatory agency. However, additional elements are subject to inspection (as described in ICH Q10).

V. KNOWLEDGE MANAGEMENT (5)

Table 5. Q&A for Section V (5) of ICH Q8, Q9, and Q10 (R5)

Date of Approval		Questions	Answers
1	Oct. 2024	How has the implementation of ICH Q8, Q9, and Q10 changed the significance and use of knowledge management?	ICH Q10 defines knowledge management as “systematic approach to acquiring, analyzing, storing, and disseminating information related to products, manufacturing processes and components.” Knowledge Management is not a new concept. It is always important regardless of the development approach. ICH Q10 highlights knowledge management because it is expected that more complex information generated by appropriate approaches (e.g., QbD, PAT, real-time data generation, and control monitoring systems) need to be captured, managed and shared during product life cycle. In conjunction with Quality Risk Management, Knowledge Management can facilitate the use of concepts such as prior knowledge (including from other similar products), development of design space, control strategy, technology transfer, and continual improvement across the product life cycle.
2	April 2009	Does ICH Q10 suggest an ideal way to manage knowledge?	No. ICH Q10 provides a framework and does not prescribe how to implement knowledge management. Each company decides how to manage knowledge, including the depth and extent of information assessment based on their specific needs.

Contains Nonbinding Recommendations

Date of Approval		Questions	Answers
3	Oct. 202	What are examples of sources of information for Knowledge Management?	<p>Some examples of knowledge sources are:</p> <ul style="list-style-type: none"> • Prior knowledge based on experience obtained from similar processes (internal knowledge, industry, scientific and technical publications) and published information (external knowledge: literature and peer-reviewed publications); • Pharmaceutical development studies;
			<ul style="list-style-type: none"> • Mechanism of action; • Structure/function relationships; • Technology transfer activities; • Process validation studies; • Manufacturing experience e.g.: <ul style="list-style-type: none"> - Internal and vendor audits; - Raw material testing data; • Innovation; • Continual improvement; • Change management activities; • Stability reports; • Product Quality Reviews/Annual Product Reviews; • Complaint Reports; • Adverse event reports (Patient safety); • Deviation Reports, Recall Information; • Technical investigations and/or CAPA reports; • Suppliers and Contractors; • Product history and /or manufacturing history; • Ongoing manufacturing processes information (e.g., trends); • Risk assessments and other quality risk management activities. <p>Information from the above can be sourced and shared across a site or company, between companies and suppliers/contractors, products and across different disciplines (e.g., development, manufacturing, engineering, quality units).</p>

Contains Nonbinding Recommendations

Date of Approval		Questions	Answers
4	Apr. 2009	Is a specific dedicated computerized information management system required for the implementation of knowledge management with respect to ICH Q8, Q9 and Q10?	No, but such computerized information management systems can be invaluable in capturing, managing, assessing, and sharing complex data and information.
5	Oct. 2024	Do regulatory agencies expect to see a formal knowledge management approach during inspections?	No. There is no regulatory requirement for a formal knowledge management system. However, it is expected that knowledge from different processes and systems is appropriately utilized. Note: ‘formal’ in this context means a structured approach using a recognized methodology or (IT-) tool, executing and documenting something in a transparent and detailed manner.

VI. SOFTWARE SOLUTIONS (6)

Table 6. Q&A for Section VI (6) of ICH Q8, Q9, and Q10 (R5)

Date of Approval		Questions	Answers
1	Oct. 2024	Is it necessary for a pharmaceutical firm to purchase products that are marketed as ‘ICH compliant solutions’ or ICH Q8, Q9, and Q10 Implementation software, etc. to achieve a successful implementation of these ICH guidances within their companies?	No. ICH has not endorsed any commercial products and does not intend to do so. ICH is not a regulatory agency with reviewing authority and thus does not have a role in determining or defining ‘ICH compliance’ for any commercial products. If considering such products, firms will need to carry out their own evaluation of these products relative to their business needs. Computer system validation studies should be performed by companies to evaluate the reliability of potential software.

REFERENCES

The following references are available on the Search for FDA Guidance Documents web page at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>. We update guidances periodically. To make sure you have the most recent version of a guidance, check the FDA Drugs guidance web page.

ICH Q8(R2) *Pharmaceutical Development* (November 2009)

Part I: Pharmaceutical Development'

Part II: Pharmaceutical Development (Annex)

ICH Q9(R1) *Quality Risk Management* (May 2023)

ICH Q10 *Pharmaceutical Quality Systems* (April 2009)